[{"data":1,"prerenderedAt":25},["ShallowReactive",2],{"$fabHdupoi8GcKh57v_ymaX9CDwGHCZSdEyxlndND5B5A":3},{"card":4,"examId":6,"chapterTitle":22,"prev":23,"next":24},{"id":5,"examId":6,"prompt":7,"answer":8,"choices":9,"questionType":14,"explanation":15,"explanationDetail":16,"mistakeHint":16,"lectureRef":16,"storyRef":16,"chapterSlug":17,"sectionCode":18,"sectionTitle":19,"clusterSlug":20,"term":16,"sequenceOrder":16,"regionWeight":16,"revisionMark":16,"isActive":21},"ch5-043","touhan","医療用医薬品から一般用医薬品に初めてスイッチされた成分の安全性調査期間はどれか。",2,[10,11,12,13],"概ね8年","概ね5年","概ね3年","概ね1年","four","医療用医薬品で使用されていた有効成分を一般用医薬品に初めて配合したものは、承認後概ね3年間の安全性調査および調査結果の報告が求められます。",null,"chapter-5","5-II-1","副作用情報等の収集","fukusayou-shuushuu",true,"第5章 医薬品の適正使用・安全対策","ch5-042","ch5-044",1784619074268]